MX2007016469A - Metodos de tratamiento utilizando ansamicinas de hidroquinona. - Google Patents

Metodos de tratamiento utilizando ansamicinas de hidroquinona.

Info

Publication number
MX2007016469A
MX2007016469A MX2007016469A MX2007016469A MX2007016469A MX 2007016469 A MX2007016469 A MX 2007016469A MX 2007016469 A MX2007016469 A MX 2007016469A MX 2007016469 A MX2007016469 A MX 2007016469A MX 2007016469 A MX2007016469 A MX 2007016469A
Authority
MX
Mexico
Prior art keywords
methods
treatment
hydroquinone
hydroquinone ansamycins
ansamycins
Prior art date
Application number
MX2007016469A
Other languages
English (en)
Inventor
Emmanuel Normant
Yun Gao
Julian Adams
Louis Grenier
James R Porter
James L Wright
Julia Brain
Asimina T Georges-Evangelinos
David Grayzel
Roger H Pak
Vito Palombella
Jeffrey K Tong
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of MX2007016469A publication Critical patent/MX2007016469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invencion proporciona metodos para tratar desordenes hiperproliferantes tales como cancer administrando compuestos de ansamicina de hidroquina.
MX2007016469A 2005-07-13 2006-07-13 Metodos de tratamiento utilizando ansamicinas de hidroquinona. MX2007016469A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/180,314 US20060019941A1 (en) 2003-12-23 2005-07-13 Analogs of benzoquinone-containing ansamycins and methods of use thereof
PCT/US2006/027113 WO2007009007A2 (en) 2005-07-13 2006-07-13 Methods of treatment using hydroquinone ansamycins

Publications (1)

Publication Number Publication Date
MX2007016469A true MX2007016469A (es) 2008-04-22

Family

ID=37637939

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007016469A MX2007016469A (es) 2005-07-13 2006-07-13 Metodos de tratamiento utilizando ansamicinas de hidroquinona.

Country Status (16)

Country Link
US (1) US20060019941A1 (es)
EP (1) EP1904057B1 (es)
JP (1) JP2009501234A (es)
KR (1) KR20080030093A (es)
CN (1) CN101267816A (es)
AT (1) ATE451919T1 (es)
AU (1) AU2006268196A1 (es)
BR (1) BRPI0612870A2 (es)
CA (1) CA2612506A1 (es)
DE (1) DE602006011161D1 (es)
ES (1) ES2337397T3 (es)
IL (1) IL188355A0 (es)
MX (1) MX2007016469A (es)
NO (1) NO20080304L (es)
WO (1) WO2007009007A2 (es)
ZA (1) ZA200800906B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2547343C (en) 2003-12-23 2013-05-14 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
WO2006098761A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
WO2007002093A2 (en) * 2005-06-21 2007-01-04 Infinity Discovery, Inc. Ansamycin formulations and methods of use thereof
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008128063A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
EP2190291B1 (en) 2007-08-23 2015-10-14 The Regents of The University of Colorado, A Body Corporate Hsp90 inhibitors with modified toxicity
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
AU2009283157B2 (en) * 2008-08-21 2015-02-26 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
WO2010045442A1 (en) * 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions
US20120108563A1 (en) * 2009-05-19 2012-05-03 Infinity Pharmaceuticals, Inc. Methods Of Treating Liposarcoma
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
RU2701645C2 (ru) 2014-05-01 2019-09-30 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии фактора комплемента в
CN114259564B (zh) * 2021-11-30 2023-03-14 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用
CN115227692A (zh) * 2022-09-05 2022-10-25 中国医学科学院基础医学研究所 Reblastatin在制备治疗慢性惊厥的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
DE3234203A1 (de) * 1981-09-17 1983-07-07 Takeda Chemical Industries, Ltd., Osaka Macbecin-derivate und deren herstellung
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
HU9401936D0 (en) * 1992-01-06 1994-09-28 Pfizer Process and uses for 4,5-diohydrogeldanamycin and its hydroquinone
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
EP0706516A1 (en) * 1993-06-29 1996-04-17 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
ES2268068T3 (es) * 2001-03-30 2007-03-16 The Usa, Represented By The Secretary, Dept. Of Health And Human Services National Institutes Health Derivado de geldanamicina util para el tratamiento del cancer.
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
DE60327994D1 (de) * 2002-02-08 2009-07-30 Conforma Therapeutics Corp Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
CA2547343C (en) * 2003-12-23 2013-05-14 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
WO2006098761A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor

Also Published As

Publication number Publication date
BRPI0612870A2 (pt) 2010-11-30
ES2337397T3 (es) 2010-04-23
CA2612506A1 (en) 2007-01-18
IL188355A0 (en) 2008-08-07
US20060019941A1 (en) 2006-01-26
EP1904057B1 (en) 2009-12-16
ZA200800906B (en) 2009-07-29
ATE451919T1 (de) 2010-01-15
EP1904057A2 (en) 2008-04-02
AU2006268196A1 (en) 2007-01-18
DE602006011161D1 (de) 2010-01-28
NO20080304L (no) 2008-02-29
WO2007009007A3 (en) 2007-05-03
CN101267816A (zh) 2008-09-17
JP2009501234A (ja) 2009-01-15
WO2007009007A2 (en) 2007-01-18
KR20080030093A (ko) 2008-04-03

Similar Documents

Publication Publication Date Title
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
TW200510303A (en) Novel compounds
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
HUS1300076I1 (hu) Diaril-hidantoin vegyületek
TW200716141A (en) Compositions and methods for treatment for neoplasms
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
GB2466912A (en) Compositions and methods for treating lysosomal disorders
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
MY186456A (en) Quinazoline carboxamide azetidines
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
TW200728258A (en) Novel compounds
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
TW200744577A (en) Method for treating osteoarthritis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal